PEG-Modified Pectin-Adriamycin Conjugate for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pectin-adriamycin conjugates are poorly soluble in water, leading to inefficient systemic administration and limited accumulation in malignant tumor tissues, resulting in reduced anti-tumor effects and increased toxicity.
Innovation Solution
A pectin-adriamycin conjugate with a modified structure incorporating polyethylene glycol (PEG), an enzymatic cleaving group, a self-degrading group, and adriamycin, which is synthesized through specific chemical reactions to enhance solubility and targeting efficacy, allowing for prolonged accumulation in tumor tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If pectin is directly bonded to adriamycin via amide bond or acylhydrazone bond, then the conjugate can be formed, but it becomes hardly soluble in water and requires preparation into nano-suspension or lyophilized powder for injection
Solution Approach 1:
The patent introduces a PEG linker as an intermediary component between pectin and adriamycin. This PEG-based linker acts as a solubility-enhancing mediator that maintains the conjugate's water solubility while enabling the bonding between pectin and adriamycin, thus resolving the contradiction between ease of manufacture and ease of operation.
2Ease of operation
If the conjugate is prepared into nano-suspension or lyophilized powder for injection, then it can be administered, but it can only be locally administrated and is easily phagocytized by the reticuloendothelial system
Solution Approach 1:
The patent creates a composite structure consisting of pectin, PEG linker, and adriamycin. This composite material design allows the conjugate to maintain water solubility for systemic administration while incorporating targeting moieties that enable active targeting of tumor cells, thereby improving both administration capability and targeting reliability simultaneously.
3Quantity of substance
If systemically administrated, the conjugate is easily phagocytized by the reticuloendothelial system, but if locally administrated, it cannot be accumulated in malignant tumor tissue for a long time with high concentration
Solution Approach 1:
The patent modifies the chemical parameters of the conjugate by incorporating PEG linkers with specific molecular weights and introducing active targeting moieties. These parameter changes reduce the conjugate's recognition by the reticuloendothelial system while enhancing its accumulation in tumor tissue through active targeting, thus resolving the contradiction between drug concentration in tumor and phagocytosis resistance.
4Reliability
If the conjugate has limited targeting effect, then it cannot accumulate in tumor tissue effectively, but if using direct bonding method, then the structure is simple, however the solubility and systemic administration are compromised
Solution Approach 1:
The patent segments the conjugate structure into distinct functional modules: pectin as the carrier, PEG linker for solubility and flexibility, and active targeting moieties for tumor-specific recognition. This segmentation allows each component to perform its specific function optimally, achieving high targeting reliability while maintaining reasonable structural complexity through modular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified pectin-adriamycin conjugate achieves enhanced anti-tumor effects with reduced toxicity by maintaining high concentrations in tumor tissues, improving chemotherapy outcomes for solid malignant tumors.
Implementation Method 1
some drugs that enter the circulatory system after injection can be accumulated in a tumor tissue by use of the enhanced permeability and retention effect (EPR) of the tumor tissue to the macromolecular substance
Implementation Method 2
PAC is gradually phagocytized by tumor cells in the tumor tissue and hydrolyzed in lysosomes to release adriamycin
Implementation Method 3
PAC is gradually phagocytized by tumor cells in the tumor tissue and hydrolyzed in lysosomes to release adriamycin
Data Source
AI summary
The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.